New drug duo targets tough breast cancer in early trial
NCT ID NCT03641755
First seen Dec 12, 2025 · Last updated Apr 24, 2026 · Updated 17 times
Summary
This study tests a combination of two drugs, olaparib and sapacitabine, in people with advanced breast cancer that has a BRCA gene mutation. The main goals are to find the safest dose and see if the drugs shrink tumors. About 10 participants are enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Broad Institute of MIT
Cambridge, Massachusetts, 02142, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.